Systemic inflammation in patients with COPD and pulmonary hypertension

被引:220
作者
Joppa, Pavol
Petrasova, Darina
Stancak, Branislav
Tkacova, Ruzena
机构
[1] Fac Med, Dept Resp Med, Kosice 04190, Slovakia
[2] L Pasteur Teaching Hosp, Kosice 04190, Slovakia
[3] Safarik Univ, Fac Med, Inst Expt Med, Kosice, Slovakia
[4] E Slovakian Inst Heart Dis, Kosice, Slovakia
关键词
COPD; C-reactive protein; pulmonary hypertension; systemic inflammation; tumor necrosis factor-alpha;
D O I
10.1378/chest.130.2.326
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Study objectives: COPD is a systemic disorder that is associated with increases of inflammatory proteins in systemic circulation. However, no data on the potential role of systemic inflammation in pulmonary hypertension secondary to COPD are available. Therefore, our aim was to investigate the degree of systemic inflammation reflected by circulatory levels of C-reactive protein (CRP), tumor-necrosis factor (TNF)-alpha, and interleukin (IL)-6 in COPD patients with and without pulmonary hypertension. Design: Cross-sectional study. Setting: University hospital, tertiary referral setting. Patients and measurements: In 43 consecutive patients with COPD (mean [+/- SD] age, 65.0 +/- 10.5 years; mean FEV1, 46.2 +/- 18.1% predicted), lung function was assessed using body plethysmography; pulmonary artery pressure (Ppa) levels were measured by echocardiography. Serum TNF-alpha and IL-6 levels were assessed by enzyme-linked immunosorbent assay, and high-sensitivity serum CRP levels were measured by chemiluminescent immunoassay. Results: Pulmonary hypertension was present in 19 patients and was absent in 24 patients. In patients with pulmonary hypertension, serum CRP and TNF-alpha levels were significantly higher than in those patients without hypertension (median, 3.6 mg/L [25th to 75th percentile, 1.4 to 13.0 mg/L] vs 1.8 mg/L [25th to 75th percentile, 0.8 to 2.8 mg/L; p = 0.034]; and median, 4.2 pg/mL [25th to 75th percentile, 3.4 to 10.9 pg/mL] vs 3.1 pg/mL [25th to 75th percentile, 2.1 to 4.2 pg/mL]; p = 0.042, respectively). No differences were seen in serum IL-6 (median, 10.4 pg/mL [25th to 75th percentile, 8.8 to 12.2 pg/mL] vs 10.5 pg/mL [25th to 75th percentile, 9.4 to 39.1 pg/mL]; p = 0.651) between the groups. In multiple linear regression analysis, the following two variables were independent predictors of systolic Ppa (R-2 = 0.373): Pao(2) (p = 0.011); and log-transformed serum CRP level (p = 0.044). Conclusion: We conclude that increases in Ppa in patients with COPD are associated with higher serum levels of CRP and TNF-alpha, raising the possibility of a pathogenetic role for low-grade systemic inflammation in the pathogenesis of pulmonary hypertension in COPD patients.
引用
收藏
页码:326 / 333
页数:8
相关论文
共 35 条
[1]   Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease [J].
Arcasoy, SM ;
Christie, JD ;
Ferrari, VA ;
Sutton, MS ;
Zisman, DA ;
Blumenthal, NP ;
Pochettino, A ;
Kotloff, RM .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2003, 167 (05) :735-740
[2]   PULMONARY VASCULAR ABNORMALITIES AND VENTILATION-PERFUSION RELATIONSHIPS IN MILD CHRONIC OBSTRUCTIVE PULMONARY-DISEASE [J].
BARBERA, JA ;
RIVEROLA, A ;
ROCA, J ;
RAMIREZ, J ;
WAGNER, PD ;
ROS, D ;
WIGGS, BR ;
RODRIGUEZROISIN, R .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1994, 149 (02) :423-429
[3]   Pulmonary hypertension in chronic obstructive pulmonary disease [J].
Barberà, JA ;
Peinado, VI ;
Santos, S .
EUROPEAN RESPIRATORY JOURNAL, 2003, 21 (05) :892-905
[4]   Diagnosis and differential assessment of pulmonary arterial hypertension [J].
Barst, RJ ;
McGoon, M ;
Torbicki, A ;
Sitbon, O ;
Krowka, MJ ;
Olschewski, H ;
Gaine, S .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (12) :40S-47S
[5]   TNF POTENTIATES PAF-INDUCED PULMONARY VASOCONSTRICTION IN THE RAT - ROLE OF NEUTROPHILS AND THROMBOXANE A(2) [J].
CHANG, SW .
JOURNAL OF APPLIED PHYSIOLOGY, 1994, 77 (06) :2817-2826
[6]   Biomarkers as prognostic factors in pulmonary arterial hypertension. Rationale and study design [J].
Cracowski, JL ;
Yaici, A ;
Sitbon, O ;
Reynaud-Gaubert, M ;
Renversez, JC ;
Pison, C ;
Faure, P ;
Cracowski, C ;
Chouri, N ;
Chaouat, A ;
Chabot, F ;
Schwedhelm, E ;
Maas, R ;
Degano, B ;
Mornex, JF ;
Humbert, M .
REVUE DES MALADIES RESPIRATOIRES, 2004, 21 (06) :1137-1143
[7]   CONTINUOUS WAVE DOPPLER DETERMINATION OF RIGHT VENTRICULAR PRESSURE - A SIMULTANEOUS DOPPLER-CATHETERIZATION STUDY IN 127 PATIENTS [J].
CURRIE, PJ ;
SEWARD, JB ;
CHAN, KL ;
FYFE, DA ;
HAGLER, DJ ;
MAIR, DD ;
REEDER, GS ;
NISHIMURA, RA ;
TAJIK, AJ .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1985, 6 (04) :750-756
[8]   Inflammation in pulmonary arterial hypertension [J].
Dorfmüller, P ;
Perros, F ;
Balabanian, K ;
Humbert, M .
EUROPEAN RESPIRATORY JOURNAL, 2003, 22 (02) :358-363
[9]   Inflammatory response and body composition in chronic obstructive pulmonary disease [J].
Eid, AA ;
Ionescu, AA ;
Nixon, LS ;
Lewis-Jenkins, V ;
Matthews, SB ;
Griffiths, TL ;
Shale, DJ .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2001, 164 (08) :1414-1418
[10]   C-reactive protein and NT-proBNP as surrogate markers for pulmonary hypertension in Gaucher disease [J].
Elstein, D ;
Nir, A ;
Klutstein, M ;
Rudensky, B ;
Zimran, A .
BLOOD CELLS MOLECULES AND DISEASES, 2005, 34 (03) :201-205